Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application

NCT06233357 · clinicaltrials.gov ↗

COMPLETED

Status

95

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
Outcome, Fatal
Tocilizumab
Interleukin 6
Critically Ill

Interventions

DRUG: treated without (N), with casirivimab / imdevimab (C) or tocilizumab (T), solely, or in combination of both (C + T)

Sponsor

University of Ulm